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OBJECTIVES This study evaluated the effect of statin therapy on mortality in individuals with significant
coronary artery disease (CAD) stratified by age.
BACKGROUND Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) significantly reduce mor-
bidity and mortality in individuals with CAD. Unfortunately, the large statin trials excluded
individuals over 80 years old, and it is therefore unknown whether very elderly individuals
benefit from statins as do younger individuals.
METHODS A cohort of 7,220 individuals with angiographically defined significant CAD (70%) was
included. Statin prescription was determined at hospital discharge. Patients were followed up
for 3.3  1.8 years (maximum 6.8). Patients were grouped by age (65, 65 to 79, and 80
years) to determine whether statin therapy reduced mortality in an age-dependent manner.
RESULTS Average age was 65  12 years; 74% were male; and 31% had a postmyocardial infarction
status. Overall mortality was 16%. Elderly patients were significantly less likely to receive
statins than younger patients (80 years: 19.8%; 65 to 79 years: 21.1%; 65 years: 28.0%; p
 0.001). Mortality was decreased among statin recipients in all age groups:80 years: 29.5%
among patients not taking a statin versus 8.5% of those taking a statin (adjusted hazard ratio
[HR] 0.50, p 0.036); 65 to 79 years: 18.7% vs. 6.0% (HR 0.56, p 0.001); and65 years:
8.9% vs. 3.1% (HR 0.70, p  0.097).
CONCLUSIONS Statin therapy is associated with reduced mortality in all age groups of individuals with
significant CAD, including very elderly individuals. Although older patients were less likely
to receive statin therapy, they received a greater absolute risk reduction than younger
individuals. More aggressive statin use after CAD diagnosis may be indicated, even in older
patients. (J Am Coll Cardiol 2002;40:1777–85) © 2002 by the American College of
Cardiology Foundation
Although individuals of all ages are affected by coronary
artery disease (CAD), most new coronary events occur in
older persons, and about 85% of people who die from CAD
are age 65 or older (1). A variety of landmark clinical trials
have demonstrated the ability of hydroxymethylglutaryl
coenzyme A reductase inhibitor (statin) therapy to signifi-
cantly decrease myocardial infarction (MI), stroke, and
cardiovascular mortality among patients with CAD (2–4).
Likewise, it has since been demonstrated that the applica-
tion of these trial findings to clinical practice can result in
significant reductions in death and MI in a wide range of
patients with CAD (5).
However, despite this extensive evidence of a clinical
benefit of statin therapy, derived from studies of tens of
thousands of patients with CAD, the question still remains
of whether statins benefit elderly patients. This is largely
due to the historical exclusion of older individuals from
major lipid trials. For the most part, major lipid trials have
excluded older patients, with only those younger than 75
years of age included in the Cholesterol And Recurrent
Events (CARE) study and the Long-term Intervention
with Pravastatin in Ischemic Disease (LIPID) study (70
years in the Scandinavian Simvastatin Survival Study [4S])
(2–4) and those younger than 80 years of age included in
the Heart Protection Study (6). In addition, subgroup
analyses highlighting the efficacy of statins in older sub-
populations have only recently been published (7–9), but
these still did not include patients older than 75 years of age.
Studies demonstrating differences in the relationship
between cholesterol and risk between younger and older
individuals have further justified the question of statin
therapy efficacy among elderly individuals. For instance,
clinical studies have not been able to show a direct relation-
ship between mortality and elevated cholesterol in elderly
individuals (2,10), even though demonstrations of such a
correlation have been made in pooled data of a broad age
range of subjects (11). Most recently, the Honolulu Heart
Study demonstrated that it was actually those with low
cholesterol who had a significant association with mortality
(12), clearly opposite of the results from studies of the
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relationship between cholesterol and mortality in younger
individuals.
As a result, statins continue to be less utilized in older
patients with CAD. Observational results cite utilization
rates in elderly individuals that lag well behind the statin
prescription rates in younger individuals (13). A significant
percentage of patients with CAD are older than 80 years of
age (1); therefore, it is important to determine whether
statin therapy is warranted in this group of patients.
METHODS
Study objectives. The objective of this study was to deter-
mine the effect of statin therapy on mortality in three age
groups of patients with angiographically defined significant
CAD: 65, 65 to 79, and 80 years.
Study population. The study consisted of a cohort of 7,220
patients who were found to have angiographically defined
significant CAD (70% stenosis in at least one major
coronary vessel). Study participants were selected among a
consecutive cohort of 13,529 patients who had been admit-
ted with symptoms or clinical findings suggestive of CAD
and underwent coronary arteriography between October
1993 and December 1999 at the LDS Hospital (Salt Lake
City, Utah) (14). Subjects were of unrestricted age and
gender who gave written, informed consent for blood to be
drawn at angiography for use in confidential blood bank
studies approved by the hospital’s institutional review board
and who survived the hospital period. Patients were strati-
fied into three age categories:65, 65 to 79, and80 years.
Age categories were chosen to coincide with cut-points
from previous clinical trials.
Clinical variables. Patient information was entered into a
computerized database, as previously described (15). These
data included age, gender, hyperlipidemia, hypertension,
smoking, family history of coronary heart disease, renal
failure, diabetes, congestive heart failure (CHF), previous
MI, previous stroke, presenting diagnosis, number of dis-
eased vessels, and type of treatment. Hyperlipidemia was
reported by the physician and determined by a serum
cholesterol value 240 mg/dl (6.2 mmol/l) or current
antihyperlipidemic treatment. Hypertension was reported
by the physician and defined as a history of systolic blood
pressure 160 mm Hg, a diastolic blood pressure 90 mm
Hg, or use of antihypertensive therapy. Tobacco use was
considered present in subjects who were active smokers or
who had a smoking history of 10 pack-years. Family
history was considered positive if a first-order relative had a
cardiovascular death, MI, or coronary revascularization be-
fore age 65 years. Renal failure was considered present if
reported by the physician or if the serum creatinine level was
2.0 mg/dl. Diabetes was determined by the presence of a
diagnosis, fasting blood glucose 126 mg/dl, or use of
antidiabetic medication. Congestive heart failure was deter-
mined by the physician report and by linking International
Classification of Diseases (ICD-9) codes in the patient’s
medical record. Previous stroke was determined by linking
ICD-9 codes in the patient’s medical record. Previous MI
was reported by the physician at the time of angiography.
The clinical presentation at index hospitalization was cate-
gorized as stable angina (stable exertional symptoms only),
unstable angina (progressive symptoms or symptoms at
rest), or MI (creatine kinase-MB fraction [CK-MB] 6
mg/dl and CK-MB index 3%). For initial management,
patients were stratified into those receiving, during the
initial hospital period, either coronary artery bypass graft
surgery (CABG), percutaneous coronary intervention
(PCI), or medical therapy alone. Prescription of beta-
blocker, angiotensin-converting enzyme inhibitor, and sta-
tin therapy was determined at hospital discharge. Assess-
ment of CAD was made by a review of the coronary
angiogram by the patient’s cardiologist, and the number of
diseased vessels was determined from this review. All data
were entered into the catheterization laboratory database in
a format modified after the Coronary Artery Surgery Study
protocol (16).
Follow-up and determination of outcomes. Patients were
followed to determine the incidence of all-cause mortality;
their mean follow-up was 3.3  1.8 years (maximum 6.8).
Death was determined from the Social Security death
registry, death certificates, and/or telephone interviews with
a family member. Essentially, 100% follow-up was attained
by these methods.
Statistical analysis. The chi-square test was used for cat-
egorical variables, and Student t test for continuous vari-
ables, to estimate the univariate association of each variable
to mortality. The chi-square test, Fisher exact test, or t
testing was used, as appropriate, to compare co-variates with
statin status in each of the age groups. Graphical estimation
of age group–specific survival based on statin status was
performed by Kaplan-Meier methods.
Univariate and multivariate statistics for statin status were
determined using Cox proportional hazards regression
(SPSS version 10.0), and potential confounding of statin
therapy was determined by inclusion of individual co-
variates in bivariate and multivariate analyses. Age-specific
models of the mortality risk associated with statin use were
built for each age stratum, with adjustment for the co-
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variates noted earlier. Models were built using conditional,
stepwise regression and were refined, using forced entry of
co-variates to build the final models. An additional
analysis was performed with multivariate Cox regression of
the overall population to evaluate any interaction between
statin therapy and age on mortality. Two-tailed p values
are presented, and the threshold for significance was p 
0.05.
RESULTS
Patient characteristics. Of the 7,220 patients included in
this study, 45% (n  3,256) were 65 years old, 46% (n 
3,309) were 65 to 79 years old, and 9% (n  655) were 80
or older. Ages ranged from 19 to 97 years. Table 1
summarizes the baseline patient characteristics for each age
category based on statin status. Overall, the patients’ average
age was 65  12 years; 75% (n  5,399) were male, and
25% (n  1,821) were female. Thirty-one percent (n 
2,256) had a post-MI status.
Statin therapy. Statins were prescribed to 24.1% (n 
1,741) of study patients at discharge from the index hospi-
talization. Table 1 shows the proportion of patients dis-
charged on statins by age category. In each of the three age
groups, individuals with a history of hyperlipidemia were
more likely to receive a statin, and those with diabetes or
CHF were less likely to receive a statin. Among individuals
80 years old, those with a previous MI or stroke were
more likely to receive statin therapy. In general, statin
therapy was more often prescribed in younger patients and
decreased in older groups (p  0.001). Statin prescription
rates changed little with age for those 65 years old;
however, after an individual reached 65 years of age, there
was an abrupt drop-off in the percentage of those receiving
statin therapy.
Clinical follow-up. In analysis by age groups, the effect of
statin therapy was not diminished by age. All-cause mor-
tality was significantly reduced in each age group in those
receiving statin therapy, compared with those not receiving
statin therapy, and the absolute benefit from statin therapy
was greatest for the very old (Fig. 1). Death rates were
Table 1. Baseline Characteristics of the Three Age-Stratified Groups
Characteristic
Age <65 Years Age 65–79 Years Age >80 Years
No Statin Statin No Statin Statin No Statin Statin
Statin prescription 72.0% 28.0% 78.9% 21.1% 80.2% 19.8%
Demographics
Age (yrs) 54.4  7.3 53.6  7.3* 71.8  4.2 71.7  4.1 82.9  2.9 83.3  3.2
Gender (female) 19% 19% 28% 30% 39% 54%*
Cardiac risk factors
Diabetes 16% 8%† 16% 9%† 11% 5%‡
Family history 36% 47%† 31% 42%† 22% 33%*
Hypertension 51% 52% 57% 68%† 58% 72%*
Hyperlipidemia 51% 71%† 44% 74%† 35% 65%†
Smoking 37% 37% 19% 22% 12% 7%
Renal failure 2.2% 0.4%† 1.0% 1.9% 2.7% 0.8%
CHF 8% 6% 15% 10%† 21% 12%‡
Stroke history 1.3% 1.1% 2.0% 2.4% 3.4% 12.3%†
MI history 23.9% 26.8% 23.1% 25.3% 18.7% 30.0%*
Presentation
Stable angina 45% 32% 52% 38% 49% 25%
Unstable angina 22% 23% 24% 30% 21% 29%
Acute MI 32% 46%† 24% 33%‡ 30% 47%†
Coronary anatomy
One vessel 46% 51% 34% 36% 29% 28%
Two vessels 27% 27% 27% 26% 27% 36%
Three vessels 27% 23%* 39% 38% 45% 36%
Treatment type
Medical only 36% 20% 41% 30% 48% 29%
PCI 41% 65% 30% 50% 31% 61%
CABG 24% 15%‡ 29% 20% 21% 11%
Concomitant medications
ACE inhibitor 35.4% 75.0%† 38.4% 75.7%† 45.3% 81.4%†
Beta-blocker 22.0% 58.5%† 20.2% 53.0%† 23.3% 59.7%†
Statistical comparisons are within the age group for statin versus no statin. For presentation of CAD, coronary anatomy, and
treatment type, p values are shown for the trend across the three categories. *p  0.01; †p  0.001; ‡p  0.05.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; CHF  congestive heart failure;
MI  myocardial infarction; PCI  percutaneous coronary intervention.
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reduced by absolute amounts of 5.8%, 12.7%, and 21.0% in
individuals 65 years, 65 to 79 years, and 80 years,
respectively. Univariate Kaplan-Meier survival curves are
shown in Figure 2. In univariate Cox regression entering
only statin status, all three age groups showed significant
benefit from statins. Hazard ratios (HRs) from univariate
survival analyses are summarized in Table 2 (age 65 years:
HR 0.52, 95% confidence interval [CI] 0.35 to 0.79; age 65
to 79 years: HR 0.53, CI 0.38 to 0.73; age 80 years: HR
0.49, CI 0.26 to 0.93).
Survival analysis and multivariate adjustment. In multi-
variate Cox regression analysis controlling for demographic
data, risk factors, and clinical variables, statins retained a
clinically profound benefit regardless of age group. Kaplan-
Meier survival curves based on statin status in each age
group are shown in Figure 3, along with the adjusted hazard
ratio estimates and p values for statins.
In Cox regression among patients 65 years of age,
statins had a 30% adjusted risk reduction (HR 0.70, CI
0.46 to 1.07, p  0.097). This reduction, however, was
not statistically significant in the final regression model,
which included statin therapy, diabetes, renal failure, beta-
blocker therapy, age, male gender, hypertension, CHF,
coronary anatomy, and treatment type (PCI or CABG)
(Table 2).
Cox regression among patients 65 to 79 years of age
showed that statins reduced the adjusted risk of death by
44% (HR 0.56, CI 0.41 to 0.77, p  0.001). As mentioned
earlier, diabetes reduced the significance of statins, but renal
failure did not. Other variables included in the final regres-
sion model included age, hypertension, CHF, coronary
anatomy, type of treatment, presentation (unstable angina
MI), previous stroke, and smoking (Table 2).
Among patients age 80 years or older, statins remained
a statistically significant and clinically important pro-
tective factor in preventing death. Statins reduced the
risk of mortality by more than 50% in this age group
(HR 0.50, CI 0.26 to 0.96, p  0.036). This risk estimate
was essentially unchanged by controlling for other co-
variates, and the effect of statins in this very elderly age
group remained greater than the risk estimates in the
younger two groups. Other co-variates that were contained
in the final regression model for the 80-and-over age group
included age, renal failure, CHF, coronary anatomy, and
smoking (Table 2).
Interestingly, in the older two age groups, smoking was
predictive of mortality among these patients with developed
CAD but was not predictive in the younger group. In the
oldest age group, a history of diabetes did not predict
increase in the risk of death, and male gender, hypertension,
and treatment type were no longer protective.
Analysis of the full population for an interaction between
statins and age showed that, in a model entering the main
Figure 1. Bar graph of mortality for patients using statins (open bars) and not using statins (solid bars) by age groups.
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effects variables and the interaction variable, the interaction
was not significant (p  0.72 for interaction).
DISCUSSION
The key finding of our study is that all age groups of
patients with CAD, even very elderly patients, receive a
clinical benefit from statin therapy. Relative risk reductions
in mortality reached 50% for those 80 years, compared
with 44% and 30% for individuals 65 to 79 years old and
those 65 years old, respectively, even after adjusting for
various potentially confounding factors. The proportionate
mortality risk was similarly reduced by statins in all age
groups, as evidenced by a nonsignificant interaction term
between statin usage and age.
Study results demonstrating a survival benefit for elderly
patients with CAD receiving statin therapy may seem to
contradict the findings of the Honolulu Heart Study (12).
In that cohort of elderly Japanese-American men (ages 71 to
93 years), low total cholesterol levels were correlated with an
increased risk of all-cause mortality, and reducing choles-
terol to low concentrations in elderly patients was ques-
tioned. However, no direct evaluation was made regarding
cholesterol-lowering therapy itself.
Our study shows that among elderly patients with CAD,
a strong association does exist between statin therapy and
mortality benefit. In fact, because more events occurred in
older patients, the absolute benefit from statin therapy was
actually greatest among the very elderly participants. Our
results are similar to results from previous studies also
demonstrating an increased absolute benefit for elderly
patients despite similar proportionate risk reductions for all
ages. For example, both the CARE and LIPID subanalyses
demonstrated an increased clinical benefit from statin ther-
apy among older patients (8,9). However, compared with
our study, which included patients up to 97 years of age, no
individuals older than 75 years of age were included in these
randomized trials.
Like previous reports on the underutilization of statins in
elderly patients (13), older patients were also significantly
less likely to receive a statin than younger individuals in this
study cohort. Although the overall rate of statin prescription
at hospital discharge in this study, which was initiated
before publication of the earliest statin trials (2), was quite
low, it was especially low in elderly patients and decreased
abruptly after 65 years of age. This is an important area of
focus, as elderly patients comprise a significant proportion
of patients with CAD and may potentially derive the
greatest benefit from statin therapy.
In addition to the positive effect of statin therapy on
all-cause mortality demonstrated in this study and others,
previous randomized trials have shown an association be-
tween statin therapy and reductions in a variety of other end
points, including stroke and CHF, which are prevalent
among older individuals. In the 4S trial, which excluded
individuals with CHF at enrollment, statin therapy was
associated with a decreased incidence of heart failure (17).
Among patients 65 to 75 years old who were enrolled in the
CARE trial, a trend toward reduced CHF was observed
among those receiving statin therapy (9). An association
between statin therapy and reduced stroke rates has also
been shown, both among patients with CAD (18) and
among those at risk of CAD (19). Because stroke and CHF
rates nearly double for each successive age decade (1), this
observation reinforces the contention that the potentially
greatest public health impact of statin therapy may be
among very elderly individuals.
Study limitations. Our study has several limitations. First,
because our study is observational, there may be uncon-
trolled confounding factors. Despite statistical adjustments
to decrease any effect due to confounders, unmeasured
differences in the study groups may persist. Next, cause-
specific mortality was not available, and we were unable to
Table 2. Final Multiple Variable Cox Regression Model







Renal failure 4.2 (2.5–6.8)
Diabetes 2.2 (1.6–3.0)
CABG 0.53 (0.37–0.76)
Coronary anatomy (per vessel) 1.3 (1.1–1.6)
Age (per decade) 1.34 (1.09–1.61)
Beta-blocker 0.54 (0.34–0.86)
PCI 0.73 (0.53–0.99)




Age (per decade) 2.0 (1.6–2.5)
CABG 0.62 (0.53–0.72)
CHF 2.6 (2.2–3.1)
Coronary anatomy (per vessel) 1.3 (1.1–1.4)
Diabetes 1.9 (1.5–2.3)
Renal failure 3.3 (2.1–5.3)




Acute MI 1.25 (1.13–1.39)
Unstable angina 1.1 (1.01–1.2)
80 years old
Statins 0.50 (0.26–0.96)
Age (per decade) 2.6 (1.6–4.3)
CHF 2.4 (1.7–3.4)
Smoking 1.8 (1.1–2.7)
Coronary anatomy (per vessel) 1.2 (0.98–1.4)
For each age group, statins are listed first, followed by co-variates according to the
level of significance.
CI  95% confidence interval; other abbreviations as in Table 1.
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Figure 2. Univariate Kaplan-Meier survival curves for statin users and nonusers among three age groups: (A) younger patients 65 years old; (B) older
patients 65 to 79 years old; and (C) very elderly patients 80 years of age or older. Continued on next page.
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determine whether those not receiving statin therapy were
more likely to die of non-cardiovascular co-morbidities.
This is especially relevant, as those receiving statins may be
healthier patients, which was evident in this study popula-
tion in that significantly fewer patients had diabetes and
CHF among those receiving statins. A potential bias, due to
the fact that there is a greater percentage of individuals with
CHF among non–statin users, may exist in all age groups,
but it may have the greatest effect among the 80-years age
group, which includes the highest prevalence of CHF. The
percentage of patients with diabetes, however, was fairly
constant in all age groups, suggesting that any diabetes-
related bias toward an increased benefit from statins would
be similar for all ages. Other risk factors, such as previous
stroke and MI, though similarly distributed among statin
users and non–statin users 80 years old, were actually
more prevalent among those 80 years old who received
statin therapy.
In addition, statin therapy was ascertained at the time of
hospital discharge, and follow-up compliance data were not
available for the entire population. We have previously
demonstrated, however, that a majority of patients pre-
scribed a statin at hospital discharge remain on long-term
statin therapy (20). Likewise, individuals who do not receive
a statin at hospital discharge are not likely to receive one
during a follow-up period. However, if the actual drop-in/
drop-out rates are high, this would have actually decreased
the apparent benefit from statin therapy observed in our
study.
Finally, cholesterol levels were not available for the
majority of participants, and we did not correlate statin
therapy and the subsequent risk of mortality with the dose
of drug or degree of cholesterol lowering. Studies that may
be nearing completion and/or are in publication, including
the PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) (21) and Heart Protection Study (6), will
provide additional information about the relationship be-
tween statin therapy, degree of cholesterol lowering, and
subsequent outcomes in patients with preexisting vascular
disease or a high cardiovascular risk.
Conclusions. Based on this large observational study, we
conclude that statin prescription at hospital discharge is
associated with similar proportionate reductions in all age
groups of patients with known CAD, including very elderly
patients. Indeed, there was an increased absolute risk
reduction among elderly patients due to an overall increased
risk at baseline. Hence, more aggressive use of statins
among patients with diagnosed CAD, including elderly
patients, appears to be indicated. Because this study focused
on patients with established CAD, future studies of statin
usage among elderly patients are required to assess their
potential for primary prevention of CAD.
Figure 2 Continued.
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Figure 3. Multivariate adjusted Kaplan-Meier survival curves for statin users and nonusers among the age groups: (A) younger patients 65 years old; (B)
older patients 65 to 79 years old; and (C) very elderly patients 80 years of age or older. Although the absolute survival rates differed substantially across the
age groups, statins had clinically profound benefits for all age groups of patients with coronary artery disease. HR  hazard ratio. Continued on next page.
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